Improved anticancer treatments

A technology for cancer treatment and anticancer drugs, which is applied in the direction of antineoplastic drugs, medical preparations containing active ingredients, drug combinations, etc., and can solve problems such as narrow therapeutic index

Inactive Publication Date: 2011-02-02
PHARMA MAR U
View PDF12 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most have a very narrow therapeutic index. In addition, cancer cells exposed to slightly less than lethal concentrations of chemotherapeutic drugs may develop resistance to similar agents and often develop cross-resistance to several other antineoplastic agents Medicinal properties

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved anticancer treatments
  • Improved anticancer treatments
  • Improved anticancer treatments

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0149] Example 1 In vivo study to determine the effect of aplidine in combination with sorafenib in human renal tumor xenografts.

[0150] The goal of the study was to assess the ability of aplidine to potentiate the antitumor activity of sorafenib by using three xenograft models of human renal carcinoma.

[0151] Female athymic nude mice (Harlan Sprague Dawley, Madison, WI) were used in all experiments. When the mice were 5 weeks old, tumor fragments or cell suspensions were implanted into the mice. Animals were housed in ventilated rack cages, 5 mice per cage, with food and water ad libitum. Mice were acclimated for 1 week prior to implantation with tumor fragments or cell suspension. The vehicle control group contained 15 mice, and the treatment groups had 10 mice each.

[0152] The tumor models used in this study were the CAKI-1 cell line, which is a human renal clear carcinoma cell line from ATCC (Manassas, VA), the MRI-H-121 cell line, and the A498 cell line, so The ...

Embodiment 3

[0304] Example 3 In vivo study to determine the effect of the combination of aplidine and temsirolimus on human renal tumor xenografts.

[0305] The goal of this study was to assess the ability of aplidine to potentiate the antitumor activity of temsirolimus by using a xenograft model of human renal carcinoma.

[0306] Female athymic nude mice (Harlan Sprague Dawley, Madison, WI) were used in all experiments. Tumor fragments were implanted into mice when they were 5 weeks old. Animals were housed in ventilated rack cages, 5 mice per cage, with food and water provided ad libitum. Mice were acclimated for 1 week prior to implantation with tumor fragments. The vehicle control group contained 15 mice, and the treatment groups had 10 mice each.

[0307] The tumor model used for the study was the MRI-H-121 cell line, which is a human renal carcinoma cell line from the DCT tumor bank. For the MRI-H-121 test, use a trocar to place the 3mm 3 Tissue tumor fragments from an in viv...

Embodiment 4

[0333] Example 4 In vivo study of aplidine combined with temsirolimus for CAKI-1 therapy in human renal tumor xenografts.

[0334] Female athymic nude mice (Harlan Sprague Dawley, Madison, WI) were used in all experiments. The cell suspension was implanted into the mice when they were 6-8 weeks old. Animals were housed in ventilated rack cages with food and water provided ad libitum. Mice were acclimatized for at least 5 days prior to tumor implantation. The vehicle control group contained 15 mice, and the treatment groups had 10 mice each. The tumor model used for this study was CAKI-1, which was implanted into animals as disclosed in Example 2.

[0335] Tumor size was determined as disclosed in Example 1. When tumors grew within a mean size range of 140±34 mg (mean±SD), according to the Tumor Weights Determined by Life Module V 8.0 SP1 Tumor Tracking and Measurement Software Mice were randomized into treatment and control groups.

[0336] Treatment of CAKI-1 tumor-b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to combinations of aplidine with another anticancer drug selected from sorafenib, temsirolimus, and sunitinib, and the use of these combinations in the treatment of cancer.

Description

technical field [0001] The present invention relates to the combination of aplidine (aplidine) and other anticancer drugs, particularly other anticancer drugs selected from sorafenib, sunitinib and temsirolimus (temsirolimus), and the present invention It relates to the use of the combination in the treatment of cancer. Background of the invention [0002] Cancer occurs when cells in a part of the body begin to grow out of control. Although there are many types of cancer, they all arise from the uncontrolled growth of abnormal cells. Cancer cells can invade adjacent tissues and spread to other parts of the body through the bloodstream and lymphatic system. There are several main types of cancer. Epithelial carcinoma is a malignant tumor arising from the uncontrolled and progressive abnormal growth of epithelial cells. Epithelial cells cover the inner and outer surfaces of the body, including organs, the lining of vessels, and other small cavities. Sarcomas are cancers t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00A61K38/15A61K31/436A61K31/4412A61K31/404
CPCA61K31/436A61K38/15A61K31/404A61K31/44A61K45/06A61P35/00A61P43/00A61K2300/00
Inventor 多琳·莱帕赫巴勃罗曼努埃尔·阿维莱斯马林玛丽亚何塞·纪廉纳瓦罗
Owner PHARMA MAR U
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap